ERBB2 and triple-negative breast carcinoma: Fourteen patients were excluded from the final analysis, seven patients were lost to follow-up, and the others did not meet the eligibility criteria (i.e., four patients had triple-negative breast cancer, and three had HER2+ breast cancer).